The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationGreaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationRole of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,174
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationFong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationBouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Escribano-Díaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T. F., Tkáč, J., Cook, M. A., Rosebrock, A. P., Munro, M., Canny, M. D., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.001 · Cited by 900
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 773
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Self-citationABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Chapman, J. R., Barral, P., Vannier, J.-B., Borel, V., Steger, M., Tomas-Loba, A., Sartori, A. A., Adams, I. R., Batista, F. D., & Boulton, S. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.002 · Cited by 606
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., & de Lange, T. (2013) · Science · doi:10.1126/science.1231573 · Cited by 603
Norquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
The emerging landscape of breast cancer susceptibility
Stratton, M. R., & Rahman, N. (2008) · Nature Genetics · doi:10.1038/ng.2007.53 · Cited by 487
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Dobzhansky, T. (1946) · Genetics · doi:10.1093/genetics/31.3.269 · Cited by 427
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 426
Self-citationBrenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 415
Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., Strawn, S., Wick, M. J., Martell, J., & Sidransky, D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0233 · Cited by 406
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., et al. (2013) · Science · doi:10.1126/science.1230624 · Cited by 401
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Self-citationGraeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327
Self-citationCao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 309
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
Brenner, J. C., Feng, F. Y., Han, S., Patel, S., Goyal, S. V., Bou-Maroun, L. M., Liu, M., Lonigro, R., Prensner, J. R., Tomlins, S. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3648 · Cited by 290
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 265
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 262
BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair
Bunting, S. F., Callén, E., Kozak, M. L., Kim, J. M., Wong, N., López-Contreras, A. J., Ludwig, T., Baer, R., Faryabi, R. B., Malhowski, A., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.015 · Cited by 252
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination–Defective Cells
Gottipati, P., Vischioni, B., Schultz, N., Solomons, J., Bryant, H. E., Djureinovic, T., Issaeva, N., Sleeth, K., Sharma, R. A., & Helleday, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4716 · Cited by 227
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 172
Self-citationOplustilova, L., Wolanin, K., Mistrik, M., Korinkova, G., Simkova, D., Bouchal, J., Lenobel, R., Bartkova, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 163
Vilar, E., Bartnik, C. M., Stenzel, S. L., Raskin, L., Ahn, J., Moreno, V. R., Mukherjee, B., Iniesta, M. D., Morgan, M. A., Rennert, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1120 · Cited by 154
McCabe, N., Lord, C. J., Tutt, A. N. J., Martin, N. M. B., Smith, G. C. M., & Ashworth, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.9.2141 · Cited by 148
Self-citationFunctional Viability Profiles of Breast Cancer
Brough, R., Frankum, J. R., Sims, D., Mackay, A. G., Mendes‐Pereira, A. M., Bajrami, I., Costa-Cabral, S., Rafiq, R., Ahmad, A. S., Cerone, M. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0107 · Cited by 140
Self-citationEvolutionary plasticity of genetic interaction networks
Tischler, J., Lehner, B., & Fraser, A. G. (2008) · Nature Genetics · doi:10.1038/ng.114 · Cited by 131
Patel, A. G., Flatten, K. S., Schneider, P. A., Dai, N. T., McDonald, J. S., Poirier, G. G., & Kaufmann, S. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296475 · Cited by 111
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 106
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 93
RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
Nakada, S., Yonamine, R. M., & Matsuo, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1057 · Cited by 58
Ikeda, H., Matsushita, M., Waisfisz, Q., Kinoshita, A., Oostra, A. B., Nieuwint, A. W. M., de Winter, J. P., Hoatlin, M. E., Kawai, Y., Sasaki, M. S., et al. (2003) · PubMed · Cited by 55
Balmañà, J., Domchek, S. M., Tutt, A. N. J., & Garber, J. E. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0048 · Cited by 49
Pennington, K. P., Wickramanayake, A., Norquist, B. M., Pennil, C. C., Garcia, R. L., Agnew, K. J., Taniguchi, T., Welcsh, P. L., & Swisher, E. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.007 · Cited by 31
Cited by
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Self-citationLord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Self-citationHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
DNA repair, genome stability and cancer: a historical perspective
Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.4 · Cited by 774
Metadata
- Authors
- Lord, C. J., & Ashworth, A.
- Venue
- Nature Medicine
- Published
- 2013-10-07
- Volume
- 19
- Issue
- 11
- Pages
- 1381-1388
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1993043513
- Cited by
- 449
- References
- 55
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.